

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, placebo-controlled, phase 1/2a clinical trial (APPROACH)

Lancet, The

392, 232-243

DOI: [10.1016/s0140-6736\(18\)31364-3](https://doi.org/10.1016/s0140-6736(18)31364-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Human Vaccines & Immunotherapeutics: News. Human Vaccines and Immunotherapeutics, 2018, 14, 2099-2100.	1.4	0
3	HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. Retrovirology, 2018, 15, 74.	0.9	26
4	Post-translational Modification-Based Regulation of HIV Replication. Frontiers in Microbiology, 2018, 9, 2131.	1.5	31
5	Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine, 2018, 36, 6744-6751.	1.7	15
6	A new step towards an HIV/AIDS vaccine. Lancet, The, 2018, 392, 192-194.	6.3	9
7	<scp>HIV</scp></scp>AIDS</scp> Vaccines: 2018. Clinical Pharmacology and Therapeutics, 2018, 104, 1062-1073.	2.3	32
8	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Animals, 2019, 9, 526.	1.0	11
9	â€Mosaicâ€™™ HIV vaccine to be tested in thousands of people across the world. Nature, 2019, 572, 165-166.	13.7	8
10	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Vaccines, 2019, 7, 82.	2.1	11
11	Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia. Journal of Virology, 2019, 93, .	1.5	19
12	Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice. Frontiers in Immunology, 2019, 10, 1429.	2.2	6
13	Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV,the, 2019, 6, e406-e410.	2.1	1
14	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports, 2019, 28, 877-895.e6.	2.9	36
15	Impact of HIV-1 Diversity on Its Sensitivity to Neutralization. Vaccines, 2019, 7, 74.	2.1	17
16	Novel prime-boost vaccine strategies against HIV-1. Expert Review of Vaccines, 2019, 18, 765-779.	2.0	34
17	Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials. Expert Review of Vaccines, 2019, 18, 1029-1041.	2.0	26
18	Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization. Cell Reports, 2019, 29, 1756-1766.e8.	2.9	47
19	CD8 + Cytotoxic-T-Lymphocyte Breadth Could Facilitate Early Immune Detection of Immunodeficiency Virus-Derived Epitopes with Limited Expression Levels. MSphere, 2019, 4, .	1.3	3

#	ARTICLE	IF	CITATIONS
20	A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	26
21	Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor. <i>Science Advances</i> , 2019, 5, eaax3567.	4.7	69
22	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
23	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	46
24	A Sample-Sparing Multiplexed ADCP Assay. <i>Frontiers in Immunology</i> , 2019, 10, 1851.	2.2	42
25	Therapeutic Potential and Biological Applications of Cordycepin and Metabolic Mechanisms in Cordycepin-Producing Fungi. <i>Molecules</i> , 2019, 24, 2231.	1.7	61
26	Effect of Fc Receptor Genetic Diversity on HIV-1 Disease Pathogenesis. <i>Frontiers in Immunology</i> , 2019, 10, 970.	2.2	10
27	Current advances in HIV vaccine preclinical studies using Macaque models. <i>Vaccine</i> , 2019, 37, 3388-3399.	1.7	16
28	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	2.2	14
30	The Antibodiome Mapping the Humoral Immune Response to HIV. <i>Current HIV/AIDS Reports</i> , 2019, 16, 169-179.	1.1	13
31	Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models. <i>Journal of Virology</i> , 2019, 93, .	1.5	37
32	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 91.	1.8	10
33	Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. <i>Nature Communications</i> , 2019, 10, 741.	5.8	46
34	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	18
35	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
36	Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations. <i>Npj Vaccines</i> , 2019, 4, 54.	2.9	27
37	Clinical and evolutionary consequences of HIV adaptation to HLA. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 194-204.	1.5	6
38	HIV-1 phylogenetics and vaccines. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 227-232.	1.5	6

#	ARTICLE	IF	CITATIONS
39	Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 253-264.	1.5	10
40	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. <i>Vaccines</i> , 2019, 7, 209.	2.1	25
41	Î±vÎ²3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26. <i>Journal of Virology</i> , 2019, 93, .	1.5	27
42	Global and regional molecular epidemiology of HIV-1, 1990â€“2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 143-155.	4.6	255
43	T cell-based strategies for HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 713-722.	1.4	39
44	Targeting Antigen to the Surface of EVs Improves the InÂVivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 108-125.	1.8	34
45	Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology. <i>Vaccine</i> , 2020, 38, 187-193.	1.7	5
46	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet</i> , The, 2020, 395, 384-388.	6.3	44
47	Recent insights into Fc-mediated effector responses to HIV-1. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 282-289.	1.5	11
48	Advances in simian-human immunodeficiency viruses for nonhuman primate studies of HIV prevention and cure. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 275-281.	1.5	7
49	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
50	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , the, 2020, 7, e688-e698.	2.1	58
51	Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2033-2041.	1.4	2
52	Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 95, .	1.5	5
53	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. <i>Npj Vaccines</i> , 2020, 5, 91.	2.9	286
54	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588.	13.7	765
55	Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada. <i>BMC Public Health</i> , 2020, 20, 1081.	1.2	1
56	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	2.9	11

#	ARTICLE	IF	CITATIONS
57	Tracking the Trajectory of Functional Humoral Immune Responses Following Acute HIV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1744.	2.2	4
58	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	1.6	10
60	The need to reassess our approaches at HIV cure and prevention. <i>Aids</i> , 2020, 34, 2141-2143.	1.0	2
61	Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. <i>Lancet HIV</i> , 2020, 7, e772-e781.	2.1	51
62	A Zigzag but Upward Way to Develop an HIV-1 Vaccine. <i>Vaccines</i> , 2020, 8, 511.	2.1	5
63	Review of preventative HIV vaccine clinical trials in South Africa. <i>Archives of Virology</i> , 2020, 165, 2439-2452.	0.9	18
64	Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26 and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 595-607.	1.9	27
65	Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1001-1046.	1.3	7
66	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2020, 20, 1061-1070.	4.6	36
67	Therapeutic Vaccines for the Treatment of HIV. <i>Translational Research</i> , 2020, 223, 61-75.	2.2	14
68	The search for an HIV vaccine, the journey continues. <i>Journal of the International AIDS Society</i> , 2020, 23, e25506.	1.2	13
69	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. <i>Frontiers in Immunology</i> , 2020, 11, 984.	2.2	9
70	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	2.9	43
71	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. <i>Future Drug Discovery</i> , 2020, 2, FDD25.	0.8	1
72	Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 909.	2.2	96
73	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	15.2	43
74	Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost. <i>Vaccines</i> , 2020, 8, 106.	2.1	10
75	COVID-19 Vaccines: ‘Warp Speed’ Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	1.5	79

#	ARTICLE	IF	CITATIONS
76	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 0.0 rgBT / Overlock 10	2.0	19
77	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	2.9	21
78	CD8+ T cells in HIV control, cure and prevention. <i>Nature Reviews Immunology</i> , 2020, 20, 471-482.	10.6	163
79	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination. <i>Vaccine</i> , 2020, 38, 1678-1689.	1.7	2
80	Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. <i>Expert Review of Vaccines</i> , 2020, 19, 133-142.	2.0	19
81	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. <i>Expert Review of Vaccines</i> , 2020, 19, 71-84.	2.0	12
82	Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope. <i>Vaccines</i> , 2020, 8, 64.	2.1	11
83	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
84	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. <i>Vaccines</i> , 2020, 8, 171.	2.1	6
85	Adenoviral Vectors Meet Gene Editing: A Rising Partnership for the Genomic Engineering of Human Stem Cells and Their Progeny. <i>Cells</i> , 2020, 9, 953.	1.8	19
86	Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years. <i>Journal of Infectious Diseases</i> , 2020, 222, 979-988.	1.9	78
87	A primer to gene therapy: Progress, prospects, and problems. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 54-71.	1.7	9
88	Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review. <i>Journal of Infectious Diseases</i> , 2021, 223, 370-380.	1.9	50
89	Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2021, 39, 3081-3101.	1.7	51
90	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
91	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
92	Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. <i>Journal of Infectious Diseases</i> , 2021, 223, 699-708.	1.9	43
94	HIV vaccinology: 2021 update. <i>Seminars in Immunology</i> , 2021, 51, 101470.	2.7	31

#	ARTICLE	IF	CITATIONS
95	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	6.0	88
96	Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center. <i>Npj Vaccines</i> , 2021, 6, 15.	2.9	5
97	Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
98	Overview of Nonhuman Primate Models of SARS-CoV-2 Infection. <i>Comparative Medicine</i> , 2021, 71, 411-432.	0.4	11
99	Evidence of a tolerogenic vaccine against AIDS in the Chinese macaque prefigures a potential human vaccine. <i>Archives of Virology</i> , 2021, 166, 1273-1282.	0.9	1
100	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 202-209.	3.6	110
101	HIV-1 Envelope Glycosylation and the Signal Peptide. <i>Vaccines</i> , 2021, 9, 176.	2.1	5
102	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. <i>Journal of Immunology</i> , 2021, 206, 1266-1283.	0.4	8
103	Lack of Molecular Mimicry between Nonhuman Primates and Infectious Pathogens: The Possible Genetic Bases. <i>Global Medical Genetics</i> , 2021, 08, 032-037.	0.4	3
104	Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	2.1	3
105	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 657424.	2.2	2
106	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262
107	Novel approaches for vaccine development. <i>Cell</i> , 2021, 184, 1589-1603.	13.5	145
108	Ad26.COVS protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. <i>Npj Vaccines</i> , 2021, 6, 39.	2.9	38
109	Adjuvant-mediated enhancement of the immune response to HIV vaccines. <i>FEBS Journal</i> , 2022, 289, 3317-3334.	2.2	10
110	To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. <i>Viruses</i> , 2021, 13, 805.	1.5	4
111	Emerging concepts in the science of vaccine adjuvants. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 454-475.	21.5	601
112	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , 2021, 6, 50.	2.9	46

#	ARTICLE	IF	CITATIONS
113	The diversity of HIV-1 fights against vaccine efficacy: how self-assembling protein nanoparticle technology may fight back. <i>Nanomedicine</i> , 2021, 16, 673-680.	1.7	0
114	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. <i>Journal of Virology</i> , 2021, 95, .	1.5	7
115	A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594.	2.0	44
116	Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice. <i>Journal of Virology</i> , 2021, 95, .	1.5	6
118	CMV, MHC-E, and the quest for an unconventional AIDS vaccine. <i>Science Immunology</i> , 2021, 6, .	5.6	2
119	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , 2021, 24, e25749.	1.2	6
120	Functional Homology for Antibody-Dependent Phagocytosis Across Humans and Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 678511.	2.2	11
121	Psychosocial Stress Alters the Immune Response and Results in Higher Viral Load During Acute Simian Immunodeficiency Virus Infection in a Pigtailed Macaque Model of Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 224, 2113-2121.	1.9	10
122	Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. <i>Viruses</i> , 2021, 13, 837.	1.5	7
123	Interim Results of a Phase 2a Trial of Ad26.COVS.2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 1824-1835.	13.9	962
124	Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1009647.	2.1	2
125	Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	13.9	1,954
126	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 697074.	2.2	18
127	Recent advances on smart glycoconjugate vaccines in infections and cancer. <i>FEBS Journal</i> , 2022, 289, 4251-4303.	2.2	39
128	Vaccine development lessons between HIV and COVID-19. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 759-761.	4.6	3
129	Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. <i>Viruses</i> , 2021, 13, 1351.	1.5	1
130	A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. <i>Cell Reports Medicine</i> , 2021, 2, 100372.	3.3	16
131	Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases. <i>Vaccine</i> , 2021, 39, 5233-5239.	1.7	0

#	ARTICLE	IF	CITATIONS
132	Cancer Clinical Trials in Africa—An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials. <i>JCO Global Oncology</i> , 2021, 7, 1358-1363.	0.8	11
133	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
134	Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity. <i>Biomaterials</i> , 2021, 276, 121062.	5.7	12
135	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021, 10, .	2.8	12
136	Type I Interferon Promotes Humoral Immunity in Viral Vector Vaccination. <i>Journal of Virology</i> , 2021, 95, e0092521.	1.5	9
137	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. <i>Vaccines</i> , 2021, 9, 1001.	2.1	2
138	Current Status of HIV-1 Vaccines. <i>Vaccines</i> , 2021, 9, 1026.	2.1	17
139	Polyfunctional Tier 2—Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. <i>Journal of Immunology</i> , 2021, 206, 999-1012.	0.4	5
140	Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations. <i>Vaccine</i> , 2021, 39, 580-587.	1.7	7
141	Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. <i>Frontiers in Immunology</i> , 2020, 11, 607333.	2.2	21
142	Peptides to combat viral infectious diseases. <i>Peptides</i> , 2020, 134, 170402.	1.2	42
143	Shortening HIV vaccine regimens to achieve high coverage. <i>Lancet HIV</i> , 2020, 7, e377-e378.	2.1	2
144	Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	45
145	Joint epitope selection and spacer design for string-of-beads vaccines. <i>Bioinformatics</i> , 2020, 36, i643-i650.	1.8	5
151	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
152	Graph-theoretical formulation of the generalized epitope-based vaccine design problem. <i>PLoS Computational Biology</i> , 2020, 16, e1008237.	1.5	6
153	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	3.9	8
154	A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques. <i>Npj Vaccines</i> , 2021, 6, 123.	2.9	2

#	ARTICLE	IF	CITATIONS
155	Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data. <i>Journal of Autoimmunity</i> , 2021, 125, 102742.	3.0	42
162	Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa606.	0.4	2
165	Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands. <i>Journal of Virus Eradication</i> , 2018, 4, 238-247.	0.3	3
166	Current approaches to HIV vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25793.	1.2	35
167	Virus-based vaccine vectors with distinct replication mechanisms differentially infect and activate dendritic cells. <i>Npj Vaccines</i> , 2021, 6, 138.	2.9	2
168	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	2.1	1
169	Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People With and Without Human Immunodeficiency Virus: A Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
170	Viral Vector Vaccines. , 2021, , .		0
171	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047.	3.7	14
172	Una vacuna preventiva frente al VIH. Situación actual y perspectivas. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2020, 5, 81-90.	0.0	0
173	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	3.7	24
174	So Pathogenic or So What? A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research. <i>Viruses</i> , 2022, 14, 135.	1.5	5
175	Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein. <i>Vaccine</i> , 2022, 40, 574-586.	1.7	15
176	Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates. <i>Vaccines</i> , 2022, 10, 187.	2.1	2
177	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	1.1	6
178	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540.	1.5	225
179	A multiclade env gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	15.2	80
180	Fighting Fire with Fire: Immunogenicity of Viral Vected Vaccines against COVID-19. <i>Viruses</i> , 2022, 14, 380.	1.5	4

#	ARTICLE	IF	CITATIONS
181	Peptides for Vaccine Development. ACS Applied Bio Materials, 2022, 5, 905-944.	2.3	26
182	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins, 2022, 14, 138.	1.5	6
183	Human adenovirus type 26 basic biology and its usage as vaccine vector. Reviews in Medical Virology, 2022, 32, e2338.	3.9	4
184	HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS Pathogens, 2022, 18, e1010369.	2.1	5
185	COVID-19 vaccination and HIV-1 acquisition – Authors’ reply. Lancet, The, 2022, 399, e36.	6.3	0
186	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses. Journal of Virology, 2022, , e0003422.	1.5	7
187	Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COVID-19 Vaccine. Journal of Infectious Diseases, 2022, 226, 979-982.	1.9	7
201	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	2.9	4
202	Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunological Reviews, 2022, 310, 6-26.	2.8	138
203	Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis. BMJ Open, 2022, 12, e058795.	0.8	1
204	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. Journal of Immunology, 2022, 208, 2663-2674.	0.4	8
205	Immunogenicity and efficacy of Ad26.COVID-19 vaccine. Immunological Reviews, 2022, 310, 47-60.	2.8	10
206	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 2022, 10, 1450.	1.6	28
207	The use of viral vectors in vaccine development. Npj Vaccines, 2022, 7, .	2.9	73
208	CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. Current Opinion in HIV and AIDS, 2022, 17, 315-324.	1.5	10
209	HIV Transmission Prevention. , 2021, , 30-50.		0
210	The HIV Reservoir and Cure and Remission Strategies. , 2021, , 199-217.		0
211	Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nature Reviews Immunology, 2023, 23, 142-158.	10.6	91

#	ARTICLE	IF	CITATIONS
212	HLA-II-Associated HIV-1 Adaptation Decreases CD4 ⁺ T-Cell Responses in HIV-1 Vaccine Recipients. <i>Journal of Virology</i> , 0, .	1.5	0
213	Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
214	Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells. <i>EBioMedicine</i> , 2022, 84, 104253.	2.7	8
215	Developing capacity for implementation and evaluation of vaccine trials in Uganda: Perspective of the Makerere University Walter Reed Project. <i>African Health Sciences</i> , 2022, 22, .	0.3	0
216	Strategies targeting hemagglutinin cocktail as a potential universal influenza vaccine. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
217	Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens. <i>PLoS Computational Biology</i> , 2022, 18, e1010624.	1.5	1
218	Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study. <i>Journal of Infectious Diseases</i> , 2023, 227, 939-950.	1.9	4
219	Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
220	Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets. <i>Npj Vaccines</i> , 2022, 7, .	2.9	0
221	Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2023, 1867, 130288.	1.1	4
222	Adaptation to HLA-associated immune pressure over the course of HIV infection and in circulating HIV-1 strains. <i>PLoS Pathogens</i> , 2022, 18, e1010965.	2.1	0
224	Ad26.COVS and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. <i>Cell Reports Medicine</i> , 2023, 4, 101018.	3.3	3
225	Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines. <i>Current Opinion in Immunology</i> , 2023, 80, 102282.	2.4	5
226	Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	4
227	Efficacy and Safety of an Ad26.RSV,preF RSV preF Protein Vaccine in Older Adults. <i>New England Journal of Medicine</i> , 2023, 388, 609-620.	13.9	41
228	Parainfluenza virus 5 is a next-generation vaccine vector for human infectious pathogens. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
229	Immune Response to HIV-1 Infection and Vaccine Development. , 0, .		0
230	Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial. <i>Vaccine</i> , 2023, 41, 2696-2706.	1.7	2

#	ARTICLE	IF	CITATIONS
231	Nano-vaccines for gene delivery against HIV-1 infection. Expert Review of Vaccines, 2023, 22, 315-326.	2.0	1
232	CD8+ Lymphocytes from Healthy Blood Donors Secrete Antiviral Levels of Interferon-Alpha. Viruses, 2023, 15, 894.	1.5	0
235	Prevention, treatment and cure of HIV infection. Nature Reviews Microbiology, 2023, 21, 657-670.	13.6	21
242	Human Immunodeficiency Virus Vaccines. , 2023, , 458-483.e15.		0